Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson's disease

AR Carta, T Simuni - Expert Opinion on Investigational Drugs, 2015 - Taylor & Francis
Introduction: Current treatment of Parkinson's disease (PD) is limited to symptomatic
dopaminergic therapy, while no interventions have been shown to slow down disease …

Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats

AA Martinez, MG Morgese, A Pisanu, T Macheda… - Neurobiology of …, 2015 - Elsevier
Long-term administration of l-3, 4-dihydroxyphenylalanine (levodopa), the mainstay
treatment for Parkinson's disease (PD), is accompanied by fluctuations in its duration of …

The role of PPAR-gamma receptor in pruritus

S Ostadhadi, V Nikoui, A Haj-Mirzaian… - European Journal of …, 2015 - Elsevier
Recent studies have clarified the novel mediators and neuronal pathways involved in itch
transmission, which might result in introduction of new therapies for management of pruritus …

Efectos protectores de la oleoiletanolamida en la neuroinflamación inducida por la administración de lipopolisacárido o por el consumo intensivo de alcohol

M Antón Valadés - 2015 - docta.ucm.es
CRH: Factor liberador de corticotropina DAMP: Patrón molecular endógeno de respuesta al
daño tisular FAAH: Ácido graso aminohidrolasa GC: Glucocorticoides GP-NAE: Glicerofosfo …

[PDF][PDF] TESIS DOCTORAL Efectos protectores de la oleoiletanolamida en la neuroinflamación inducida por la administración de lipopolisacárido o por el consumo …

MA Valades - 2015 - docta.ucm.es
CRH: Factor liberador de corticotropina DAMP: Patrón molecular endógeno de respuesta al
daño tisular FAAH: Ácido graso aminohidrolasa GC: Glucocorticoides GP-NAE: Glicerofosfo …